These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36546322)

  • 21. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
    Koch T; Lahu S; Coughlan JJ; Cassese S; Voll F; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Angiolillo DJ; Sibbing D; Kastrati A; Kufner S
    Thromb Haemost; 2023 Apr; 123(4):464-477. PubMed ID: 36442805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
    Motovska Z; Hlinomaz O; Miklik R; Hromadka M; Varvarovsky I; Dusek J; Knot J; Jarkovsky J; Kala P; Rokyta R; Tousek F; Kramarikova P; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    Circulation; 2016 Nov; 134(21):1603-1612. PubMed ID: 27576777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Implications of Immature Platelet Fraction at 5-Year Follow-up Among ACS Patients Treated With Dual Antiplatelet Therapy.
    Gumiężna K; Baruś P; Sygitowicz G; Wiśniewska A; Bednarek A; Zabłocki J; Piasecki A; Klimczak-Tomaniak D; Kochman J; Grabowski M; Tomaniak M
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231202864. PubMed ID: 38196286
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
    Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
    Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
    Ndrepepa G; Kastrati A; Menichelli M; Neumann FJ; Wöhrle J; Bernlochner I; Richardt G; Witzenbichler B; Sibbing D; Gewalt S; Angiolillo DJ; Hamm CW; Hapfelmeier A; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Mayer K
    JACC Cardiovasc Interv; 2020 Oct; 13(19):2238-2247. PubMed ID: 33032712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry.
    Al Raisi S; Protty M; Raposeiras-Roubín S; D'Ascenzo F; Abu-Assi E; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores-Blanco P; Varbella F; Cespón-Fernández M; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Cequier Á; Gaita F; Alexopoulos D; Valgimigli M; Íñiguez-Romo A; Kinnaird T
    Minerva Cardiol Angiol; 2021 Aug; 69(4):408-416. PubMed ID: 34137238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
    Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
    Bonhomme F; Bonvini R; Reny JL; Poncet A; Fontana P
    Platelets; 2015; 26(4):324-30. PubMed ID: 25905916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G
    J Thromb Thrombolysis; 2016 Aug; 42(2):245-53. PubMed ID: 26951167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.